Possis shareholder seeks potential purchaser
This article was originally published in Clinica
An investor whose group holds almost 5% of Possis Medical plans to open discussions with other potential buyers of the company. Jay Bernstein has already spoken to other large shareholders who have expressed an interest in "an effort to maximise the value of their stock holdings in the very near term", he says.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.